Wei Y - Search Results

1

Genetic factors in the pathogenesis of cardio-oncology.

Qi Y, Wei Y, Li L, Ge H, Wang Y, Zeng C, Ma F. Qi Y, et al. Among authors: wei y. J Transl Med. 2024 Aug 5;22(1):739. doi: 10.1186/s12967-024-05537-5. J Transl Med. 2024. PMID: 39103883 Free PMC article. Review.

2

Clinical characteristics associated with efficacy and prognosis among patients treated with PD-1/PD-L1 inhibitors for early-stage triple-negative breast cancers: A meta-analysis.

Wei Y, Wu Y, Luo Y, Ma F. Wei Y, et al. Crit Rev Oncol Hematol. 2024 Apr;196:104309. doi: 10.1016/j.critrevonc.2024.104309. Epub 2024 Feb 28. Crit Rev Oncol Hematol. 2024. PMID: 38423376 Review.

3

PP2A as a potential therapeutic target for breast cancer: Current insights and future perspectives.

Qi Y, Li L, Wei Y, Ma F. Qi Y, et al. Among authors: wei y. Biomed Pharmacother. 2024 Apr;173:116398. doi: 10.1016/j.biopha.2024.116398. Epub 2024 Mar 8. Biomed Pharmacother. 2024. PMID: 38458011 Free article. Review.

4

Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial.

Mo H, Yu Y, Sun X, Ge H, Yu L, Guan X, Zhai J, Zhu A, Wei Y, Wang J, Yan X, Qian H, Xu B, Ma F. Mo H, et al. Among authors: wei y. Nat Med. 2024 Sep;30(9):2528-2539. doi: 10.1038/s41591-024-03088-2. Epub 2024 Jul 5. Nat Med. 2024. PMID: 38969879 Clinical Trial.

5

Comparative efficacy of anthracycline-free and anthracycline-containing neoadjuvant chemoimmunotherapy regimens for triple-negative breast cancer.

Wei Y, Li Q, Mo H, Qi Y, Ge H, Sun X, Fan Y, Zhang P, Wang J, Luo Y, Wang J, Ma F. Wei Y, et al. Transl Oncol. 2024 Nov 1;51:102171. doi: 10.1016/j.tranon.2024.102171. Online ahead of print. Transl Oncol. 2024. PMID: 39488006 Free PMC article.

6

LAG3 and its emerging role in cancer immunotherapy.

Wang M, Du Q, Jin J, Wei Y, Lu Y, Li Q. Wang M, et al. Among authors: wei y. Clin Transl Med. 2021 Mar;11(3):e365. doi: 10.1002/ctm2.365. Clin Transl Med. 2021. PMID: 33784013 Free PMC article. No abstract available.

7

Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis.

Wei Y, Du Q, Jiang X, Li L, Li T, Li M, Fan X, Li Y, Kariminia S, Li Q. Wei Y, et al. Crit Rev Oncol Hematol. 2019 Jun;138:178-189. doi: 10.1016/j.critrevonc.2019.04.008. Epub 2019 Apr 15. Crit Rev Oncol Hematol. 2019. PMID: 31092375

8

Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis.

Wei Y, Li Y, Du Q, Peng X, Jin J, Guo H, Li Y, Li Q. Wei Y, et al. J Immunol Res. 2020 Dec 18;2020:5269787. doi: 10.1155/2020/5269787. eCollection 2020. J Immunol Res. 2020. PMID: 33381603 Free PMC article.

9

Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression.

Wei Y, Zhang J, Fan X, Zheng Z, Jiang X, Chen D, Lu Y, Li Y, Wang M, Hu M, Du Q, Yang L, Li H, Xiao Y, Li Y, Jin J, Wang D, Yuan X, Li Q. Wei Y, et al. Front Immunol. 2022 Jul 8;13:935552. doi: 10.3389/fimmu.2022.935552. eCollection 2022. Front Immunol. 2022. PMID: 35874784 Free PMC article.

10

Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib.

Lu Y, Jin J, Du Q, Hu M, Wei Y, Wang M, Li H, Li Q. Lu Y, et al. Among authors: wei y. Front Cell Dev Biol. 2021 Sep 9;9:730240. doi: 10.3389/fcell.2021.730240. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34568339 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24,381 results

Search Page

Filters